Orchard Therapeutics Announces Eight Presentations Across Gene Therapy Portfolio at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting
April 29, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Most Comprehensive Presentation of Orchard Clinical Data to Date; Spans Five Disease Areas and Highlights Broad Applicability of Hematopoietic Stem Cell Gene Therapy Approach Accepted Abstracts...
Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA)
April 27, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the first patient has been dosed in an...
Orchard Therapeutics Outlines Business Impact of COVID-19
March 31, 2020 16:05 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 31, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today provided an update on its business and operations, outlining how the...
Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, M.D., Ph.D., as New Chief Executive Officer
March 18, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
-- Mark Rothera steps down as President and CEO -- -- Frank Thomas takes on additional responsibilities as President and Chief Operating Officer -- BOSTON and LONDON, March 18, 2020 (GLOBE...
Orchard Therapeutics Reports 2019 Financial Results and Reviews Key Strategic Priorities for 2020
February 27, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Commercial Preparations on Track for Potential Second Half 2020 EU Launch of OTL-200 for MLD with U.S. Regulatory Filing Expected Late 2020 / Early 2021 Initiation of Rolling U.S. Regulatory Filing...
Orchard Therapeutics to Present at Investor Conferences in March
February 26, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today announced that members of the management team will present at the...
Orchard Therapeutics to Webcast Conference Call of 2019 Financial Results
February 20, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard Therapeutics Announces Presentation of Clinical Data from Neurometabolic Franchise at 16th Annual WORLD Symposium
February 10, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced upcoming presentations from its neurometabolic franchise at...
Orchard Therapeutics Appoints Industry Veteran Steven Altschuler, M.D. to its Board of Directors
February 03, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Steven Altschuler, M.D., to its board of...
Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)
January 29, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has received orphan drug designation from the U.S....